Skip to main content

Table 2 Treatment outcome of prior enzalutamide and subsequent abiraterone acetate treatment

From: Abiraterone acetate after progression with enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: a multi-center retrospective analysis

 

Enzalutamide (n = 14)

n (%)

Abiraterone (n = 14)

n (%)

Any PSA decline

13 (93)

5 (36)

PSA decline ≥30 %

9 (64)

1 (7)

PSA decline ≥50 %

7 (50)

1 (7)

Median PFS, mo (95 % CI)

5.0 (3.7–6.4)

3.4 (0.8–6.0)

Type of progression

 PSA PD

10 (72)

8 (57)

 Radiographic PD

3 (21)

5 (36)

 Clinical PD

1 (7)

1 (7)